Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Currently, physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. In this report, hepatologists and gastroenterologists reveal what attributes drive their prescribing and what they are looking for in terms of efficacy, safety, and delivery from future treatments. Using the Target Product Profile (TPP) simulator, we can establish physicians’ preference for emerging drugs and assess if these drugs can capitalize on the untapped NASH space.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European hepatologists and gastroenterologists fielded in January 2023.
Key companies: Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Akero Therapeutics, Novo Nordisk, AstraZeneca, Inventiva Pharma, Eli Lilly.
Key drugs: Obeticholic acid, resmetirom, pioglitazone, vitamin E, metformin, GLP-1 receptor agonists, SGLT-2 inhibitors, statins, ursodeoxycholic acid.